Literature DB >> 23151465

Rapalogs in cancer prevention: anti-aging or anticancer?

Mikhail V Blagosklonny1.   

Abstract

Common cancer is an age-related disease. Slow aging is associated with reduced and delayed carcinogenesis. Calorie restriction (CR), the most studied anti-aging intervention, prevents cancer by slowing down the aging process. Evidence is emerging that CR decelerates aging by deactivating MTOR (Target of Rapamycin). Rapamycin and other rapalogs suppress cellular senescence, slow down aging and postpone age-related diseases including cancer. At the same time, rapalogs are approved for certain cancer treatments. Can cancer prevention be explained by direct targeting of cancer cells? Or does rapamycin prevent cancer indirectly through slowing down the aging process? Increasing evidence points to the latter scenario.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23151465      PMCID： PMC3542224          DOI： 10.4161/cbt.22859

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  141 in total

1.  The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

2.  Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans).

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2010-03-02       Impact factor: 4.534

3.  Another "Janus paradox" of p53: induction of cell senescence versus quiescence.

Authors:  Zbigniew Darzynkiewicz
Journal:  Aging (Albany NY)       Date:  2010-06       Impact factor: 5.682

Review 4.  The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Authors:  Monica M Mita; Alain Mita; Eric K Rowinsky
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

5.  Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.

Authors:  Pankaj Kapahi; Brian M Zid; Tony Harper; Daniel Koslover; Viveca Sapin; Seymour Benzer
Journal:  Curr Biol       Date:  2004-05-25       Impact factor: 10.834

6.  DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.

Authors:  Olga V Leontieva; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

7.  Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.

Authors:  Genevieve L Weber; Marie-Odile Parat; Zev A Binder; Gary L Gallia; Gregory J Riggins
Journal:  Oncotarget       Date:  2011-11

Review 8.  Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.

Authors:  Antonio Sacco; Aldo Roccaro; Irene M Ghobrial
Journal:  Oncotarget       Date:  2010-11

9.  Exploiting the mTOR paradox for disease prevention.

Authors:  Ramiro Iglesias-Bartolome; J Silvio Gutkind
Journal:  Oncotarget       Date:  2012-10

10.  Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer.

Authors:  Jonathan D Mosley; John T Poirier; Darcie D Seachrist; Melissa D Landis; Ruth A Keri
Journal:  Mol Cancer Ther       Date:  2007-08       Impact factor: 6.261
View more
  50 in total

1.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

Review 2.  In search of antiaging modalities: evaluation of mTOR- and ROS/DNA damage-signaling by cytometry.

Authors:  Zbigniew Darzynkiewicz; Hong Zhao; H Dorota Halicka; Jiangwei Li; Yong-Syu Lee; Tze-Chen Hsieh; Joseph M Wu
Journal:  Cytometry A       Date:  2014-02-22       Impact factor: 4.355

3.  Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.

Authors:  Chuanbing Zang; Jan Eucker; Piet Habbel; Christian Neumann; Carsten-Oliver Schulz; Nikola Bangemann; Lutz Kissner; Hanno Riess; Hongyu Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

5.  Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

Authors:  Irina G Popovich; Vladimir N Anisimov; Mark A Zabezhinski; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

6.  Dysregulation of the mTOR pathway in p53-deficient mice.

Authors:  Olga V Leontieva; Liliya R Novototskaya; Geraldine M Paszkiewicz; Elena A Komarova; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

7.  LncRNA GUARDIN suppresses cellular senescence through a LRP130-PGC1α-FOXO4-p21-dependent signaling axis.

Authors:  Xuedan Sun; Rick Francis Thorne; Xu Dong Zhang; Miao He; Jinming Li; Shanshan Feng; Xiaoying Liu; Mian Wu
Journal:  EMBO Rep       Date:  2020-03-09       Impact factor: 8.807

8.  Gene expression-based risk score in diffuse large B-cell lymphoma.

Authors:  Caroline Bret; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2012-12

Review 9.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 10.  mTORC2: The other mTOR in autophagy regulation.

Authors:  Josué Ballesteros-Álvarez; Julie K Andersen
Journal:  Aging Cell       Date:  2021-07-12       Impact factor: 9.304
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.